About Mabion
MabionCD20 is a monoclonal antibody, a biosimilar to MabThera/Rituxan (rituximab), which is our company’s flagship project, has received FDA Orphan Drug Status for the indications of 2 rare diseases: membranous nephropathy and autoimmune hemolytic anemia.
Currently Mabion is a fully integrated CDMO offering a wide services associated with the development and GMP manufacturing of biotherapeutics, including monoclonal antibodies and any recombinant protein-based products (also dedicated to rare diseases). We offers an end-to-end solution, covering all stages of biologic orphan drug development from CLD through process scale-up and analytics to sterile fill and finish and QC release.
Images
